Consequences of daptomycin-mediated membrane damage in Staphylococcus aureus.
about
Quantitative proteomic view associated with resistance to clinically important antibiotics in Gram-positive bacteria: a systematic reviewCyclic lipodepsipeptides: a new class of antibacterial agents in the battle against resistant bacteriaHuman commensals producing a novel antibiotic impair pathogen colonizationAntimicrobial Peptides Targeting Gram-Positive BacteriaIdentification of an Antimicrobial Agent Effective against Methicillin-Resistant Staphylococcus aureus Persisters Using a Fluorescence-Based Screening StrategyElucidation of the Mode of Action of a New Antibacterial Compound Active against Staphylococcus aureus and Pseudomonas aeruginosaStrain Dependent Genetic Networks for Antibiotic-Sensitivity in a Bacterial Pathogen with a Large Pan-GenomeInteraction of daptomycin with lipid bilayers: a lipid extracting effectScreen for inducers of autolysis in Bacillus subtilisDaptomycin for methicillin-resistant Staphylococcus epidermidis native-valve endocarditis: a case report.Evaluation of flavonoid and resveratrol chemical libraries reveals abyssinone II as a promising antibacterial lead.Syntheses and evaluation of macrocyclic engelhardione analogs as antitubercular and antibacterial agents.Daptomycin resistance mechanisms in clinically derived Staphylococcus aureus strains assessed by a combined transcriptomics and proteomics approachDaptomycin approved in Japan for the treatment of methicillin-resistant Staphylococcus aureus.Plantazolicin is an ultra-narrow spectrum antibiotic that targets the Bacillus anthracis membrane.The membrane as a target for controlling hypervirulent Clostridium difficile infections.Effect of ester to amide or N-methylamide substitution on bacterial membrane depolarization and antibacterial activity of novel cyclic lipopeptidesDaptomycin: pharmacology and clinical use.Recent advances in antibacterial drugs.Characterizing vancomycin-resistant Enterococcus strains with various mechanisms of daptomycin resistance developed in an in vitro pharmacokinetic/pharmacodynamic model.In vitro activity of daptomycin combined with dalbavancin and linezolid, and dalbavancin with linezolid against MRSA strains.Repurposing Toremifene for Treatment of Oral Bacterial Infections.Antibiotic Combinations with Daptomycin for Treatment of Staphylococcus aureus Infections.Tert-butyl benzoquinone: mechanism of biofilm eradication and potential for use as a topical antibiofilm agent.Redox-active compounds with a history of human use: antistaphylococcal action and potential for repurposing as topical antibiofilm agentsIn vitro studies indicate a high resistance potential for the lantibiotic nisin in Staphylococcus aureus and define a genetic basis for nisin resistanceThe target of daptomycin is absent from Escherichia coli and other gram-negative pathogens.Investigation of the potential for mutational resistance to XF-73, retapamulin, mupirocin, fusidic acid, daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus isolates during a 55-passage studyFuranyl-rhodanines are unattractive drug candidates for development as inhibitors of bacterial RNA polymeraseFurther characterization of Bacillus subtilis antibiotic biosensors and their use for antibacterial mode-of-action studiesSafety analysis of high dose (>6 mg/kg/day) daptomycin in patients with concomitant statin therapy.Revisiting unexploited antibiotics in search of new antibacterial drug candidates: the case of γ-actinorhodin.Daptomycin.Enhanced killing of Escherichia coli using a combination of polyhexamethylene biguanide hydrochloride and 1-bromo-3-chloro-5,5- dimethylimidazolidine-2,4-dione.1-((2,4-Dichlorophenethyl)Amino)-3-Phenoxypropan-2-ol Kills Pseudomonas aeruginosa through Extensive Membrane Damage.Distinguishing on-target versus off-target activity in early antibacterial drug discovery using a macromolecular synthesis assay.Macromolecular synthesis and membrane perturbation assays for mechanisms of action studies of antimicrobial agents.The silver cation (Ag+): antistaphylococcal activity, mode of action and resistance studies.Molecular State of the Membrane-Active Antibiotic Daptomycin.Synthesis and Antimicrobial Activity of Novel Substituted Ethyl 2-(Quinolin-4-yl)-propanoates
P2860
Q26796165-B638BF48-F3C4-4E04-BF01-6ECCD7CE971AQ26863225-D8D4FC60-0F92-4CE0-AE5A-578DDAD9B683Q28005468-D5785B12-DF3C-4300-88E5-44BFBCE32671Q28077888-F09066A9-A61C-4822-9EF1-D0D6E77BC8D1Q28547787-28E0E166-8F20-4C9E-836D-68EB2BFF60A4Q28551971-A62C82F2-18C4-4A16-96AD-E360C80A84BFQ28553946-AB39FC84-C93A-4ED0-A05D-B601F598D4FFQ30586516-F3479AA7-BEBE-4F78-880F-6BCB38DA4BDBQ33626330-77252FF3-3204-467F-9838-349FEE5EE60DQ33718381-FAD4719E-18A9-442B-9ABD-FEE31992F0FCQ34357575-FEEEF510-67CD-49D8-9B55-3212089663BEQ34645907-B03F05DC-5974-4F51-8F3C-DF6F63B92182Q35096905-3B48ACCF-37B1-400F-9A56-CF833536871EQ35771368-2960AFDC-1517-425C-ADD9-8C467DF1B7D3Q36857331-2EB6100C-FDB1-4235-8618-2876D269BB8FQ36963920-0B007731-89D6-4057-8589-1656070098F4Q37209021-CC8194D8-9D58-4BEA-BBA3-95825C681A62Q37693931-C5746579-E6DC-4F00-92F8-72A50D5C8A7AQ38115306-0B2F9749-CFAD-42FA-A0CC-6E20FCE541D8Q38626860-923D43FD-F3CB-4D49-84CA-2D154C143A71Q40377364-67620B15-3E74-4C9C-8B0A-61284DC94C9DQ40403765-82A26EDE-FF05-470F-B8CA-F2AC6DFBCD9CQ40631566-875F0745-081C-4629-AA2C-7627CD46E5BFQ40696433-BEB9711B-0B9F-4257-89A1-77BDF59F38E3Q41678275-11E377B2-9AFF-4BFB-9C07-727032E33F34Q41885921-5263D2ED-3CB5-4455-9B78-A2C00B38E7C7Q41978763-690CCC2B-056E-4F12-97D6-DCCD437433BEQ42009908-BB089B30-BEF8-4038-8E81-34CF09CF403EQ42421156-4ECF1444-0446-4BF1-9DEB-B37DFE3FD8BDQ42706360-ABEC010D-12D7-4921-B80E-2DA43B684219Q44899027-570A7870-46EE-49A7-B426-2F8DD689A73EQ47105053-22878259-56DD-44A0-A037-9BC4EB639C70Q47616115-AB77143A-23EC-4448-979A-F89C84785E80Q47657018-C713DCF7-53C9-4BDF-BA83-EF0A5C6F9F2DQ50239822-FDEF7176-EE8A-4769-977D-A7875275ACB1Q50982185-D15A2809-DD8F-4D2A-8364-D718DA8B35EDQ52621175-EDDE5CA0-596E-496B-AB5B-E4432D490950Q52842534-86A8A4EB-34AF-4081-AD1C-8A14E7999223Q53733143-8FA2A75C-F454-4E85-8EEE-2BCBAC392C42Q56838183-62D93FAD-BBD2-4736-A798-777E36946504
P2860
Consequences of daptomycin-mediated membrane damage in Staphylococcus aureus.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Consequences of daptomycin-mediated membrane damage in Staphylococcus aureus.
@en
Consequences of daptomycin-mediated membrane damage in Staphylococcus aureus.
@en-gb
Consequences of daptomycin-mediated membrane damage in Staphylococcus aureus.
@nl
type
label
Consequences of daptomycin-mediated membrane damage in Staphylococcus aureus.
@en
Consequences of daptomycin-mediated membrane damage in Staphylococcus aureus.
@en-gb
Consequences of daptomycin-mediated membrane damage in Staphylococcus aureus.
@nl
prefLabel
Consequences of daptomycin-mediated membrane damage in Staphylococcus aureus.
@en
Consequences of daptomycin-mediated membrane damage in Staphylococcus aureus.
@en-gb
Consequences of daptomycin-mediated membrane damage in Staphylococcus aureus.
@nl
P2860
P356
P1476
Consequences of daptomycin-mediated membrane damage in Staphylococcus aureus.
@en
P2093
Ian Chopra
Joanne Karen Hobbs
P2860
P304
P356
10.1093/JAC/DKN321
P407
P577
2008-07-31T00:00:00Z